Annovis Hits Full Enrollment in Alzheimer’s Trial Ahead of Schedule
Event summary
- Annovis Bio completed enrollment of 850 patients in its Phase 3 trial for buntanetap, surpassing initial projections.
- Trial designed with two readouts: symptomatic data due Q1 2027 and disease-modifying data due Q1 2028.
- Company plans separate NDA submissions following each data readout.
- Study includes patients with pTau217-confirmed Alzheimer’s pathology across 83 U.S. clinical sites.
The big picture
Annovis’ accelerated enrollment reflects growing urgency for Alzheimer’s treatments, positioning the company as a key player in neurodegenerative disease therapeutics. The dual-readout trial design could streamline regulatory pathways but also introduces execution challenges. Success hinges on maintaining statistical power and meeting FDA expectations at each milestone.
What we're watching
- Regulatory Alignment
- Whether Annovis can maintain FDA-aligned protocol through data readouts and NDA submissions.
- Data Readout Impact
- How symptomatic and disease-modifying data will influence investor sentiment and trial momentum.
- Execution Risk
- The pace at which Annovis can transition from trial completion to regulatory approvals.
Related topics